<img src="https://ml.globenewswire.com/Resource/Download/d879f1ff-d5d7-48d7-9731-c881b469d873?size=2" nborder="0" align="left" hspace="5" vspace="5" title="NRx_Logo_300dpi.png" alt="NRx Pharmaceuticals, Inc."/><ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt;">Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other neurological conditions</li><li style="margin-top:5pt; margin-bottom:5pt;">Installation complements HOPE's interventional psychiatry platform and aligns with NRx's previously announced clinical trial of NRX-101 in combination with robotic-enabled TMS</li></ul> WEST PALM BEACH, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announced that its wholly-owned subsidiary, HOPE Therapeutics, Inc. ("HOPE"), has become the first commercial site to deploy Zeta Surgical's FDA-cleared Zeta TMS Navigation System. The system has been installed at HOPE's West Palm Beach, Florida clinic, where it will be used to deliver high-precision, image-guided Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other neurological conditions. "Being selected as the first commercial site for Zeta's FDA-cleared TMS Navigation System validates the integrated treatment model we are building at HOPE," said Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals and HOPE Therapeutics. "Zeta's AI-driven image guidance brings neurosurgical-grade targeting precision into our outpatient clinics, and it sets the stage for our planned trial of NRX-101 in combination with robotic-enabled TMS in patients with depression and suicidality." TMS is a non-invasive therapy widely used for treatment-resistant depression, which affects approximately one-third of patients with major depression. The clinical efficacy of TMS depends heavily on the accurate targeting of specific neural circuits. The Zeta TMS Navigation System uses proprietary RealTrack™ computer vision and artificial intelligence to continuously align a patient's MRI or CT scan with their facial anatomy in real time, delivering sub-millimetric precision and reducing setup times to under two minutes per session without the need for conventional fiducial markers. The deployment complements HOPE's broader interventional psychiatry platform, which includes ketamine and Spravato® delivery, TMS, Hyperbaric Oxygen Therapy, and other neuroplastic therapies offered across the HOPE network of clinics. It also aligns with NRx's previously announced clinical trial program of NRX-101 (oral D-cycloserine/lurasidone) in combination with robotic-enabled TMS for patients with depression and suicidality, which is planned to be conducted across a leading US academic teaching hospital, three HOPE Therapeutics clinics, and two military treatment facilities. About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. About HOPE Therapeutics, Inc. HOPE Therapeutics, Inc. (<a href="https://www.globenewswire.com/Tracker?data=duzIrauu2n5qMKzW7QO7T6W0Ukj4GtNmZQiVrbT6KVZWjIGuJAEEsBXdSVJ5mJTY6UKBlRFnTZ_R6PEwgMxpJCGFMAoKrHnCwfZe_iILDSnjPGQdhufAiuG4R7h0qpkL" rel="nofollow" target="_blank" title="www.hopetherapeutics.com">www.hopetherapeutics.com</a>), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine and other neuroplastic medications, transcranial magnetic stimulation (TMS), Hyperbaric Oxygen Therapy, and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. HOPE is the first network in Florida to offer the AMPA One Day (ONE-D) treatment that combines TMS, physician-prescribed D-cycloserine, and lisdexamfetamine to achieve remission from treatment-resistant depression. Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at <a href="https://www.globenewswire.com/Tracker?data=ggMmoBKMUjF-uE4sF0Kv0cuqnKJIWkEuH7HHywJQA86VzCn4h9DixZwR3zgDvkWF0BXxW2nplVB78CK4ShMMlfTmQE-CPUbq37gAUVCjTj5MZF82lV50KEbmFjflaiqlMzPc6t5vRUXM11JDoCLGiIcrRn1pu1IzlkLkkChnCu3uYPe_cx1e9ja3r2tNHCHUVal7JD5S1ohV7WB3L0etqOitVo37Q1YC7INCtDkkkI854_QqT1fZgk2UChUtMD6bKhw67Pt4XwtBDA47dMbUYaqB8kvGvhuzKs-ie0Qh4IDSVo598eYJqp72bx_kMb53r_pKfxbtKdZVHbS2cofGkPuP3q2H8nJzPWdTJ_TzkuYID4lhJ_3bN2fVejsBdYkX1vvmxFqw-OD_-xZ1hZG2uyVHL3_X9vdoPPgNeUTsuTTViE-1A4SFej_zB4TDh938caFpPqEzKvCQlt1hUiPmGpbSncn7o21eiJ237PuEStNbnhvbSuefiMgKanG0z9bA3WCYs_BkH3x1_4wYuiUJbJTnodZUVeAi-Anh7k3ygI-_7GodeNi2Ooz7hUhmD0fv7TWTQgpfNj7e2Y_g0kVNnZ0-i9fd9WDjP5w_lxEqOgWSSFNKgdunXOK0a8nfBw5d_OJZbJMRTgNQ-hevBQ_KNiiqg9heG7fXx-rJFKYGuB4sMVR1xT8EWkLWoak_a3vygcAtN2-pyE0idexenxLI1MN47cysCaLyGHQwhdRhLFdCXDdoY0Ib5nBwvJWNUnArA-wMiPxCvfdmWMxFGFQzUtQ5ajI1iRV6j6EP5xHAbO3qC237NPHkAxW-cXxLdGjM5DesGb_tltJjbCMcJrIbLvz1cvjoV4DdWcjAarT_O-5BtHlG6YDqYz7RHWhUzuek37E-aDFyoxvQHWAcDKEP4tj2SS1qja6EAwBgAV5fHtvolLye2SG5UpanN8dA9XTVc0WfEysyRwH9cv4fvRdnN24wjkTDgA19aiBwU7qrjd7QRuuwwhXgjmC4wxEWpBUUNs1LbHhc3VWFMJJNR718nKrX--x2ceNIUUS3tMjLOaNatuwLQWri4t-A4RwwM5t86OMIWX1jp3RHf36TpzTwV8V0ihaNmq6zexf-pgndsJN4famMicZseWvGgpcUG_QsR58gMP8vztEsANwkxHOZmnc24ikD_xqjGVpB4BNm2_3Rg5olCcuFIR8JaO9HCGkHC6Z3Pbyb1kqMkcazcAWK8Q==" rel="nofollow" target="_blank" title="">http://www.sec.gov</a>. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Brian Korb Managing Partner, astr partners (917) 653-5122 <a href="https://www.globenewswire.com/Tracker?data=c9tuU4A7hT064uYiZDI2joCNFDGadZ4Cpb8Hih_OyKh96APcd8V9-0ckmzdgI0uBJe3GqeDBf_K2G_KxUJW9ZP6p77zcuPFstDjeC3ppZEqTvV9sitoOlwWW8jaVuyVL" rel="nofollow" target="_blank" title="brian.korb@astrpartners.com">brian.korb@astrpartners.com</a> <img alt="" src='https://ml.globenewswire.com/media/MmRlNzY1OTUtZTA4ZS00NWQ3LWE1MmEtMjFmNjZmYjQyNzI1LTEwOTU2OTMtMjAyNi0wNS0yNy1lbg==/tiny/NRx-Pharmaceuticals-Inc.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn